Kilitch Drugs to Raise Rs 50 Crore Through Rights Issue
By Shishta Dutta | Updated at: Oct 16, 2025 04:07 PM IST
Mumbai, 2 July 2025: Kilitch Drugs (India) Ltd (BSE: 524500 | NSE: KILITCH) has approved a rights issue of equity shares amounting to ₹50 crore. The decision was finalised during the company’s board meeting held on 2 July 2025, under Regulation 30 of SEBI (LODR) Regulations, 2015. The funds will primarily support a Greenfield project in Pen, Maharashtra.
Kilitch Drugs (India) Ltd traded at ₹449.70, up ₹7.95 or 1.80%, as of 1:24 p.m. IST. The stock opened at ₹444.00, touched a high of ₹449.75 and a low of ₹436.20. With a market capitalisation of ₹723.22 crore and a P/E ratio of 27.09, the stock is trading near its 52-week high of ₹499.00, well above its 52-week low of ₹299.95.
Board Clears Rights Issue Worth ₹50 Crore to Support Expansion Plans
The board has sanctioned the issue of equity shares with a face value of ₹10 each to existing shareholders on a rights basis. The record date for eligibility will be announced separately.
Key Rights Issue Details Outlined by Kilitch Drugs
The snapshot below provides a summary of the rights issue terms:
| Particulars | Details |
|---|---|
| Type of Securities | Equity Shares |
| Mode of Issuance | Rights Issue |
| Total Fundraising Size | Up to ₹50 crore |
| Face Value per Share | ₹10 |
| Regulation Compliance | SEBI ICDR & LODR, Companies Act, 2013 |
The company will also apply for in-principle approval under Regulation 28(1) of SEBI (LODR) Regulations, 2015.
Funds to Power Greenfield Project and Strengthen Infrastructure
Kilitch Drugs plans to utilise the proceeds for the following purposes:
- Capital expenditure for a Greenfield manufacturing unit in Pen, Maharashtra
- General corporate purposes
- Rights issue-related expenses
The draft letter of offer will outline the full terms and will be shared with eligible shareholders in due course.
Board Finalises Strategy in Morning Session
The board meeting to approve the rights issue commenced at 10:30 a.m. and concluded at 12:50 p.m., where the decision was formally adopted and documented.
Managing Director Reaffirms Commitment to Transparent Execution
Mukund Mehta, Managing Director, confirmed the company’s commitment to obtaining timely approvals and keeping shareholders informed. He noted that the process will comply with the SEBI Master Circular dated 11 November 2024.
Company to Strengthen Manufacturing Presence in Domestic Market
Kilitch Drugs (India) Ltd is a BSE- and NSE-listed pharmaceutical company engaged in the manufacture and export of pharmaceutical formulations. The company operates WHO GMP-certified manufacturing facilities and is now gearing up to expand its production capacity through a Greenfield venture in Maharashtra.
Rights Issue Signals Strategic Move for Long-Term Growth
This capital raise marks a pivotal step in Kilitch Drugs’ roadmap to scale up infrastructure and drive growth. The proposed Greenfield expansion aligns with its long-term strategy to enhance operational capabilities and serve broader markets efficiently.
REF: https://nsearchives.nseindia.com/corporate/KILITCH_02072025125942_OutcomeOfBoardMeetingToStockExchanges.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
